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Abstract: Trigeminal neuralgia (TN) is a neuropathic pain condition affecting the face. It has a 
significant impact on the quality of life and physical function of patients. Evidence suggests that 
the likely etiology is vascular compression of the trigeminal nerve leading to focal demyelination 
and aberrant neural discharge. Secondary causes such as multiple sclerosis or brain tumors can 
also produce symptomatic TN. Treatment must be individualized to each patient. Carbamazepine 
remains the drug of choice in the first-line treatment of TN. Minimally invasive interventional 
pain therapies and surgery are possible options when drug therapy fails. Younger patients may 
benefit from microvascular decompression. Elderly patients with poor surgical risk may be 
more suitable for percutaneous trigeminal nerve rhizolysis. The technique of radiofrequency 
rhizolysis of the trigeminal nerve is described in detail in this review.
Keywords: interventional treatment, minimally invasive, pain management, radiofrequency 
rhizolysis, trigeminal neuralgia
Introduction
Trigeminal neuralgia (TN) is a painful condition involving the face. It is the most frequently 
diagnosed form of facial pain with a prevalence of 4 per 100,000 in the general population.1 
It commonly affects patients aged over 50 years and occurs more frequently in women 
than men with a ratio of 1.5:1 to 2:1, respectively.1 It is also more common in patients 
with multiple sclerosis (incidence of 1%–2%) and hypertension.1 TN is associated with 
decreased quality of life and impairment of daily function. It impacts upon employment 
in 34% of patients, and depressive symptoms are not uncommon.2,3 The condition may 
be severely disabling with high morbidity, particularly in the elderly.4
Pathophysiology
The pathophysiology of TN remains unclear. Evidence suggests that pain occurs 
because of pressure on the trigeminal nerve root at the entry zone into the pontine region 
of the brain stem.4,5 Compression by tumor or blood vessel may cause local pressure, 
leading to demyelination of the trigeminal nerve. Results from experimental studies 
suggest that demyelinated axons are prone to ectopic action potential generation.4,6 
Demyelination has also been shown in cases of TN associated with multiple sclerosis 
and tumor compression of the trigeminal nerve root.
Diagnosis
TN is characterized by sharp, shooting, ‘electric shock-like’ pain sensation that is 





with the maxillary branch being most commonly affected and 
the ophthalmic branch the least.1 Pain usually lasts from a 
few seconds to 2 min and may recur spontaneously between 
pain-free intervals. Most patients report a sensitive trigger 
zone that reproduces an attack of neuralgia if lightly touched. 
Routine daily activities that contact, mobilize, stretch, or even 
slightly stimulate the trigger zone, such as brushing the teeth, 
applying facial cosmetics, encountering a breeze, talking, or 
eating, may trigger intolerable pain.
The International Headache Society has published criteria 
for the diagnosis of classical or symptomatic TN (Table 1).7 
In classical TN, no etiology can be identified other than 
vascular compression. On the other hand, symptomatic TN 
is related to an underlying cause such as tumor compression 
or multiple sclerosis. It is therefore important to distinguish 
between the two as the focus in management of symptomatic 
TN is to treat the underlying cause.
Another useful classification that is commonly used may 
be more relevant to clinicians:8,9
1.  TN1 – idiopathic, spontaneous facial pain that is pre-
dominantly episodic;
2.  TN2 – idiopathic, spontaneous facial pain that is pre-
dominantly constant;
3.  Trigeminal neuropathic pain resulting from unintentional 
injury to the trigeminal nerve due to trauma or surgery;
4.  Trigeminal deafferentation pain resulting from inten-
tional injury to the nerve by peripheral nerve ablation, 
gangliolysis, or rhizotomy in an attempt to treat either 
TN or other related facial pain;
5.  Symptomatic TN due to multiple sclerosis;
6.  Post-herpetic TN following a cutaneous herpes zoster 
outbreak in the trigeminal distribution; and
7.  Atypical facial pain that refers to facial pain secondary to 
a somatoform pain disorder and requires psychological 
testing for diagnostic confirmation.
Many TN patients may also manifest a combination of 
TN1 and TN2 characteristics, together or at separate times 
during the natural course of the disease. For example, a patient 
may have a dull, nearly constant background pain in between 
paroxysmal attacks of sharp or electrical shock-like pain.
Neurological examination is usually normal in patients 
with idiopathic TN, although a subtle trigeminal sensory 
deficit may be detected occasionally.10 However, symptoms 
of TN may also be the first manifestation in patients with cer-
ebellopontine angle tumors or multiple sclerosis. Therefore, 
patients should be asked about other neurologic symptoms 
such as tingling, numbness, loss of balance, weakness in 
one or more limbs, blurred or double vision, hearing loss, 
dizziness, headaches, and fits.
Magnetic resonance imaging (MRI) scan of the brain is 
useful to exclude symptomatic TN due to multiple sclerosis 
and tumors. MRI sequences augmented by a three-dimensional 
gradient echo sequence such as fast inflow with steady-state 
precession or intravenous gadolinium–DTPA can also 
improve visualization of the vascular compression around 
the trigeminal nerve root.11
Differential diagnoses for facial pain include headache 
disorders, temporomandibular joint pain, dental pain, 
chronic sinusitis, otitis media, as well as myofascial pain. 
A discussion of these conditions is beyond the scope of this 
review. In general, the facial location, sharp or electrical 
quality, excruciating intensity, phasic temporal profile, and 
responsiveness to a specific drug can help us distinguish TN 
from other types of facial pain.10
Treatment
The treatment of patients with idiopathic TN is often a chal-
lenge in clinical practice, and conservative management with 
drug therapy is always the first-line treatment. When drugs are 
not efficacious or produce intolerable adverse effects, inter-
ventional pain treatment or surgery is the possible option.
Pharmacological treatment
Carbamazepine has been used for many decades in the treat-
ment of TN, and it is the drug of choice.12,13 Meta-analyses 
Table 1 international Headache Society diagnostic criteria for 
trigeminal neuralgia
Classical
A.   Paroxysmal attacks of pain lasting from a fraction of a second to  
2 min, affecting one or more divisions of the trigeminal nerve, and 
fulfilling criteria B and C
B. Pain has at least one of the following characteristics: 
  1. Intense, sharp, superficial, or stabbing 
  2. Precipitated from trigger zones or by trigger factors
C. Attacks are sterotyped in the individual patient
D. There is no clinically evident neurologic deficit
E.  Not attributed to another disorder
Symptomatic
A.   Paroxysmal attacks of pain lasting from a fraction of a second to 
2 min, with or without persistence of aching between paroxysms, 
affecting one or more divisions of the trigeminal nerve, and fulfilling 
criteria B and C
B. Pain has at least one of the following characteristics: 
  1. Intense, sharp, superficial, or stabbing 
  2. Precipitated from trigger zones or by trigger factors
C. Attacks are sterotyped in the individual patient
D.   A causative lesion, other than vascular compression, has been 
demonstrated by special investigations and/or posterior fossa 
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have demonstrated the efficacy of carbamazepine with a 
number-needed-to-treat of 2.5.13,14 Carbamazepine may even 
have diagnostic utility because patients with classical TN will 
respond well to it. Patients with symptomatic TN or other causes 
of facial pain are less likely to respond to carbamazepine. Doses 
of carbamazepine range between 200 and 1200 mg daily.
Other medications with reported efficacy in TN include 
oxcarbazepine, baclofen, and lamotrigine.15–17 Other 
medications such as topiramate, gabapentin, pregabalin, 
and levetiracetam have shown success in treating TN, but 
evidence is limited to small uncontrolled studies or case 
reports.15 Patients should receive an adequate trial of at 
least three drugs including carbamazepine before surgical 
or interventional treatment is considered.10
Surgical treatment
Microvascular decompression (MVD) and gamma knife 
surgery (GKS) are surgical options available to patients 
with TN.
Surgical MvD
MVD has been widely used based on the theory that vascular 
compression of the trigeminal nerve is responsible for TN.18,19 
Craniotomy is performed to separate the blood vessels from 
the trigeminal nerve using an inert sponge or felt.20 A recent 
retrospective review of patients with TN who had under-
gone MVD showed that a high proportion of patients (71%) 
reported complete pain relief 10 years after surgery.21
Mortality rate for MVD ranges from 0.2% to 0.5%. There 
is a 4% incidence of postoperative morbidity such as cerebro-
spinal fluid (CSF) leak, infarct, or hematoma formation.21
Ablative techniques
Gamma knife surgery
GKS is a noninvasive stereotactic radiosurgical technique 
that utilizes a focused beam of radiation to target the root 
of the trigeminal nerve. It is commonly performed with 
the patient under sedation. Pain relief obtained from GKS 
is delayed and usually occurs about 2 weeks later. Initial 
good pain relief can be achieved in ∼80% of patients.22,23 
However, there is a risk of recurrence after 1 year.22 GKS 
may be preferred to MVD in elderly patients because of the 
lower rate of surgical complications.24 Complications include 
facial paresthesia, hypoesthesia, and sensory loss. Anesthesia 
dolorosa has not been reported.15
Minimally invasive percutaneous techniques for treating 
TN include balloon compression, glycerol rhizolysis, and 
radiofrequency (RF) rhizotomy.
Balloon compression
In balloon compression, a small balloon is introduced percu-
taneously using a needle to compress the trigeminal ganglion. 
Pain relief was immediate in more than 80% of patients.25,26 
Complications include severe bradycardia or asystole, corneal 
anesthesia, facial sensory loss or dysesthesia, and masseter 
weakness.25 In a 20-year follow-up review, recurrence of pain 
occurred in 32% of patients over the entire study period.26
Glycerol rhizolysis
This procedure is performed with the patient in the sitting 
position with the head flexed. A needle is introduced into 
the trigeminal cistern and glycerol is injected. As glycerol is 
hyperbaric, it will sink and produce discrete neurolytic lesions 
of the second and third divisions of the trigeminal nerve. Pain 
relief has been reported to be more than 90% in one study with 
a recurrence rate of 23% after a mean period of 30 months.27
Radiofrequency rhizotomy
This review will focus on the role of RF rhizotomy in the 
treatment of TN. Patients with TN who have good to excellent 
pain relief with a diagnostic trigeminal ganglion block may 
be suitable candidates for percutaneous RF rhizotomy, espe-
cially if the pain relief is of a short duration. It is performed 
by destruction of the trigeminal ganglion or roots using RF.
RF is the most common percutaneous procedure used to 
treat TN, especially in elderly patients.
Procedure
Patients are fasted for at least 6 h before the procedure. 
Prophylactic antibiotic is administered 1 h before the proce-
dure. Intravenous access is obtained, and standard monitors 
including electrocardiogram, blood pressure monitoring, and 
pulse oximetry are applied. Sedation is usually necessary to 
increase patient comfort and reduce anxiety.
The procedure is performed under fluoroscopic guidance 
with the patient in the supine position and head extended. 
The C-arm is rotated to obtain an oblique submental view to 
visualize the foramen ovale. The skin entry point is ∼2–3 cm 
lateral to the commissura labialis (angle of the mouth) on 
the affected side. The needle trajectory follows a straight 
line directed toward the pupil when seen from the front and 
passes 3 cm anterior to the external auditory meatus when 
seen from the side.28
A 22-gauge, 10-cm RF cannula with a 5-mm active tip 
is used. After administration of local anesthesia, the cannula 
is advanced in a coaxial manner (tunnel view) to the X-ray 





placed in the oral cavity to make sure that the buccal mucosa 
has not been perforated. When the cannula enters the foramen 
ovale, the depth of the cannula inside the Meckel’s cavity is 
ascertained on the lateral fluoroscopic view. The electrode is 
advanced ∼2–4 mm further through the canal of the foramen 
ovale such that the tip of the electrode reaches the junction 
of the petrous ridge of the temporal bone and the clivus 
(Figure 2). The stylet is then removed from the cannula, 
and aspiration is performed to ensure that there is no CSF 
or blood. Injecting 0.5 mL contrast dye helps to confirm that 
the needle has not penetrated the dura.28,29
Test stimulation is mandatory before RF lesioning. The 
mandibular nerve lies in the lateral portion of the foramen 
ovale. If the nerve is stimulated at 2 Hz between 0.1 and 
1.5 Hz, muscle contraction of the lower jaw may be seen. 
This confirms that the needle has passed through the fora-
men ovale and the tip is lying on the trigeminal roots. Next, 
paresthesia in the concordant trigeminal distribution of the 
patient’s usual symptoms (V1, V2, or V3 divisions) at 50 Hz, 
1 msec pulse duration should be reproducible at 0.1–0.5 V.28,29 
If paresthesia is only obtained above 0.5 V stimulation, the 
needle should be redirected to get the same response at a 
lower voltage. After appropriate stimulation parameters have 
been achieved, 0.5 mL of 0.25% bupivacaine with 40 mg 
of triamcinolone should be injected. After waiting for at 
least 30 sec, RF lesioning at 60°C is carried out for 60 sec. 
The needle can be repositioned to repeat RF lesioning if more 
than one branch of the trigeminal nerve is involved.
Pulsed RF (PRF) is a nondestructive method of 
delivering RF energy to the trigeminal ganglion. In contrast 
to conventional RF described above, short bursts of RF 
current at 42°C are generated with long pauses between 
bursts to allow heat to dissipate in the target tissue.30 Ther-
mal lesions are not produced by PRF, but recent evidence 
suggests that microscopic damage to axonal microfilaments 
and microtubules can occur, with greater changes seen in C 
fibers than A-β or A-δ fibers.31 However, a recent randomized 
controlled trial comparing conventional RF with PRF showed 
that PRF was not effective in reducing pain in patients with 
TN.32 Therefore, PRF cannot be recommended as the standard 
therapy for rhizolysis of the trigeminal nerve.
Complications
In a large-scale, long-term follow-up of 1600 patients who 
had received percutaneous RF rhizotomy of the trigeminal 
ganglion, complications reported include diminished corneal 
reflex (5.7%), masseter weakness and paralysis (4.1%), 
dysesthesia (1%), anesthesia dolorosa (0.8%), keratitis 
(0.6%), and transient paralysis of cranial nerves III and VI 
(0.8%). Permanent cranial nerve VI palsy was observed in 
two patients, CSF leakage in two, carotid-cavernous fistula 
in one, and aseptic meningitis in one.33
Efficacy
After percutaneous RF rhizotomy, initial pain relief can 
be achieved in 98% of patients, as high as that obtained 
with MVD.28 Among the various interventional pain  Figure 2 Lateral fluoroscopic view showing needle tip at entrance of foramen ovale.
Figure 1 Left oblique submental fluoroscopic view showing needle directed toward 




RF ablation for trigeminal neuralgia
therapies, RF rhizotomy offers the highest rate of complete 
pain relief.34 Although 15%–20% of patients may experience 
recurrence pain in 12 months, recurrence rate is the lowest 
among all the percutaneous techniques.
Long-term efficacy of RF rhizolysis is comparatively 
lower than that of MVD.35 It can be repeated in the same 
patient if required. In addition, it is a viable option for poor 
surgical risk patients or for elderly patients who are not fit 
for MVD because of lower morbidity and mortality rates 
associated with RF rhizolysis.
Conclusion
It is important to rule out secondary causes of TN, especially 
in young patients or patients with bilateral symptoms sug-
gestive of multiple sclerosis. MRI scans should be obtained 
to help detect the presence of vascular compression of the 
trigeminal nerve. Medical therapy remains first line in the 
treatment of TN, and drugs such as carbamazepine and 
oxcarbazepine can be used. Surgery and interventional pain 
treatment can be considered in patients who have persistent 
pain despite drug therapy or who are unable to tolerate 
adverse effects of drugs.
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